TOWSON, Md.& RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--The Immune Deficiency Foundation (IDF) announced today the launch of an electronic newsletter that will provide important disease state and support information for the immune deficiency community. The electronic newsletter, the Primary Immune Tribune, will be delivered on a monthly basis to patients, caregivers, and professionals who comprise the community. Talecris Biotherapeutics, a leading manufacturer of liquid immune globulin intravenous (IGIV) therapy used to treat primary immune deficiency, is the exclusive supporter of the newsletter through a grant to the IDF, allowing the subscription newsletter to be available to the community for free.
